Commentary: Is The Vanishing Conduit The Answer For The Lack Of Ideal Conduit?

  • Bahaaldin Alsoufi
    Address reprint requests to Bahaaldin Alsoufi, MD, Department of Cardiovascular and Thoracic Surgery, University of Louisville School of Medicine, Norton Children's Hospital, 201 Abraham Flexner Way, Suite 1200, Louisville, KY 40202, Phone: 1 502 588 7600.
    Department of Cardiovascular and Thoracic Surgery, University of Louisville School of Medicine, Norton Children's Hospital
    Search for articles by this author
      Lack of information about rate and completeness of Xeltis conduit resorption and strength and persistent functionality of the substituting autologous tissue require longer follow-up.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Seminars in Thoracic and Cardiovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Prodan Z.
        • Mroczek T.
        • Sivalingam S.
        • et al.
        Initial clinical trial of a novel pulmonary valved conduit.
        Semin Thorac Cardiovasc Surg. 2022; 34: 985-991
        • Bennink G.
        • Torii S.
        • Brugmans M.
        • et al.
        A novel restorative pulmonary valved conduit in a chronic sheep model: Mid-term hemodynamic function and histologic assessment.
        J Thorac Cardiovasc Surg. 2018; 155: 2591-2601
        • Morales D.
        • Herrington C.
        • Bacha E.
        • et al.
        A Novel Restorative Pulmonary Valve Conduit: Early Outcomes of Two Clinical Trials.
        Front Cardiovasc Med. Accept Publ. 2021;

      Linked Article

      • Initial Clinical Trial of a Novel Pulmonary Valved Conduit
        Seminars in Thoracic and Cardiovascular SurgeryVol. 34Issue 3
        • Preview
          Valved allografts and xenografts for reconstruction of the right ventricular outflow tract (RVOT) lack durability and do not grow. We report the first clinical use of a completely bioabsorbable valved conduit (Xeltis pulmonary valve - XPV) in children. Twelve children (six male), median age five (two to twelve) years and median weight 17 (10 to 43) kg, underwent RVOT reconstruction with the XPV. Diagnoses were: pulmonary atresia with ventricular septal defect (VSD) (n = 4), tetralogy of Fallot (n = 4), common arterial trunk (n = 3), and transposition of the great arteries with VSD and pulmonary stenosis (n = 1).
        • Full-Text
        • PDF